Pulmonary fibrosis: from pathogenesis to clinical decision-making

Trends Mol Med. 2023 Sep 14:S1471-4914(23)00195-8. doi: 10.1016/j.molmed.2023.08.010. Online ahead of print.ABSTRACTPulmonary fibrosis (PF) encompasses a spectrum of chronic lung diseases that progressively impact the interstitium, resulting in compromised gas exchange, breathlessness, diminished quality of life (QoL), and ultimately respiratory failure and mortality. Various diseases can cause PF, with their underlying causes primarily affecting the lung interstitium, leading to their referral as interstitial lung diseases (ILDs). The current understanding is that PF arises from abnormal wound healing processes triggered by various factors specific to each disease, leading to excessive inflammation and fibrosis. While significant progress has been made in understanding the molecular mechanisms of PF, its pathogenesis remains elusive. This review provides an in-depth exploration of the latest insights into PF pathophysiology, diagnosis, treatment, and future perspectives.PMID:37716906 | DOI:10.1016/j.molmed.2023.08.010

Source: Trends in Molecular Medicine - September 16, 2023 Category: Molecular Biology Authors: Thomas Koudstaal Manuela Funke-Chambour Michael Kreuter Philip L Molyneaux Marlies S Wijsenbeek Source Type: research